DexCom, Inc. (NASDAQ:DXCM) has received an average rating of “Buy” from the twenty-six analysts that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, nine have issued a hold recommendation and fourteen have assigned a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $70.69.
A number of brokerages have recently issued reports on DXCM. Canaccord Genuity reiterated a “buy” rating and set a $90.00 price target on shares of DexCom in a research report on Tuesday, August 22nd. ValuEngine upgraded DexCom from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. BidaskClub upgraded DexCom from a “sell” rating to a “hold” rating in a research report on Saturday, August 19th. Barclays PLC began coverage on DexCom in a research report on Friday, September 15th. They set an “equal weight” rating and a $76.00 price target for the company. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $90.00 price target (down previously from $105.00) on shares of DexCom in a research report on Tuesday, August 8th.
In related news, EVP Steven Robert Pacelli sold 1,450 shares of the business’s stock in a transaction that occurred on Monday, September 25th. The stock was sold at an average price of $69.81, for a total value of $101,224.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Kevin R. Sayer sold 12,000 shares of the business’s stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $55.00, for a total value of $660,000.00. The disclosure for this sale can be found here. Insiders sold a total of 27,329 shares of company stock valued at $1,648,729 in the last 90 days. 1.70% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently made changes to their positions in the business. DF Dent & Co. Inc. lifted its position in DexCom by 438.2% in the third quarter. DF Dent & Co. Inc. now owns 75,856 shares of the medical device company’s stock valued at $3,711,000 after purchasing an additional 61,762 shares during the last quarter. Neuberger Berman Group LLC lifted its position in DexCom by 54.7% in the third quarter. Neuberger Berman Group LLC now owns 385,421 shares of the medical device company’s stock valued at $18,857,000 after purchasing an additional 136,205 shares during the last quarter. California Public Employees Retirement System lifted its position in DexCom by 2.0% in the third quarter. California Public Employees Retirement System now owns 129,400 shares of the medical device company’s stock valued at $6,331,000 after purchasing an additional 2,500 shares during the last quarter. Sessa Capital IM L.P. bought a new stake in DexCom in the third quarter valued at approximately $14,678,000. Finally, Zions Bancorporation lifted its position in DexCom by 36,222.2% in the third quarter. Zions Bancorporation now owns 3,269 shares of the medical device company’s stock valued at $160,000 after purchasing an additional 3,260 shares during the last quarter.
DexCom (NASDAQ DXCM) opened at $55.55 on Friday. The company has a debt-to-equity ratio of 0.84, a current ratio of 5.86 and a quick ratio of 5.50. DexCom has a twelve month low of $42.62 and a twelve month high of $88.80.
ILLEGAL ACTIVITY NOTICE: This article was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another website, it was illegally stolen and republished in violation of international copyright and trademark laws. The legal version of this article can be read at https://www.dispatchtribunal.com/2017/12/05/dexcom-inc-dxcm-given-average-recommendation-of-buy-by-analysts.html.
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.